Senseonics Holdings shares rise 3.10% intraday after signing a Memorandum of Understanding to transition commercialization and distribution of Eversense 365.

Senseonics Holdings, Inc. rose 3.10% in intraday trading, with the company announcing a Memorandum of Understanding to transition all commercialization and distribution of Eversense 365 and future products from Ascensia Diabetes Care to Senseonics. This move will allow Senseonics to assume responsibility for all global sales, marketing, and commercialization in the U.S. beginning January 1, 2026. Additionally, the company has expanded its non-dilutive debt facility up to $100 million with Hercules Capital to fund its commercial organization.